Patents by Inventor Toru Iijima
Toru Iijima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12025043Abstract: An exhaust gas processing device includes: a manifold configured to change a travelling direction of exhaust gas from a first direction to a second direction; a first catalyst carrier into which the exhaust gas that has been guided from the manifold flows, the first catalyst carrier being configured to purify the exhaust gas that is flowing in the second direction; a heater provided on the upstream of the first catalyst carrier in the flowing direction of the exhaust gas, the heater being configured to heat the exhaust gas that has entered from the manifold; and a case accommodating the first catalyst carrier and the heater, wherein an inlet-side opening portion of the case is inserted into the manifold to a position facing an inlet of the manifold, and the inlet-side opening portion is formed with an inlet-side cut-out portion configured to allow passage of the exhaust gas.Type: GrantFiled: August 3, 2022Date of Patent: July 2, 2024Assignee: Marelli CorporationInventors: Kouhei Kuroki, Shunichi Mitsuishi, Hiroaki Masubuchi, Toru Hisanaga, Toru Iijima, Yoshihiro Shiga, Takaharu Yamamoto, Masayuki Hara
-
Publication number: 20240191643Abstract: An exhaust gas processing device includes: a manifold configured to change a travelling direction of exhaust gas from a first direction to a second direction; a first catalyst carrier into which the exhaust gas that has been guided from the manifold flows, the first catalyst carrier being configured to purify the exhaust gas that is flowing in the second direction; a heater provided on the upstream of the first catalyst carrier in the flowing direction of the exhaust gas, the heater being configured to heat the exhaust gas that has entered from the manifold; and a case accommodating the first catalyst carrier and the heater, wherein an inlet-side opening portion of the case is inserted into the manifold to a position facing an inlet of the manifold, and the inlet-side opening portion is formed with an inlet-side cut-out portion configured to allow passage of the exhaust gas.Type: ApplicationFiled: August 3, 2022Publication date: June 13, 2024Inventors: Kouhei Kuroki, Shunichi Mitsuishi, Hiroaki Masubuchi, Toru Hisanaga, Toru Iijima, Yoshihiro Shiga, Takaharu Yamamoto, Masayuki Hara
-
Patent number: 11753303Abstract: A carbon nanotube array constituted by large numbers of carbon nanotubes vertically aligned on a substrate is produced by supplying a carbon source gas into a reaction vessel having a hydrogen gas atmosphere, in which a substrate on which a reaction catalyst comprising fine metal particles is formed is placed; forming large numbers of vertically aligned carbon nanotubes on the substrate by keeping a reaction temperature of 500-1100° C. for 0.5-30 minutes; and heat-treating the carbon nanotubes by stopping the supply of the carbon source gas and keeping 400-1100° C. for 0.5-180 minutes in a non-oxidizing atmosphere.Type: GrantFiled: March 22, 2019Date of Patent: September 12, 2023Assignee: SUGITA DENSEN CO., LTD.Inventors: Kenta Naka, Toru Iijima, Yuichi Sunaga, Akikazu Sugita, Shuji Tsuruoka
-
Patent number: 11279718Abstract: A method for producing an ureido group-containing organosilicon compound includes the following steps (I) and (II): (I): a step of obtaining a compound represented by formula (1) by reacting urea and an amino group-containing organosilicon compound represented by formula (3): wherein R1 represents an alkyl group having 1 to 10 carbon atoms or the like, R3 represents a hydrogen atom or the like, Me represents a methyl group, m represents an integer of 1 to 3, and n represents an integer of 1 to 12, wherein R2 represents a hydrogen atom or the like, and R1, Me, m, and n represent the same meaning as described above; and (II): a step of further reacting by supplying the amino group-containing organosilicon compound represented by formula (3) to a mixture containing a compound represented by formula (1) and urea.Type: GrantFiled: September 17, 2019Date of Patent: March 22, 2022Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Munenao Hirokami, Katsuhiro Uehara, Toru Iijima
-
Publication number: 20200087327Abstract: A method for producing an ureido group-containing organosilicon compound includes the following steps (I) and (II): (I): a step of obtaining a compound represented by formula (1) by reacting urea and an amino group-containing organosilicon compound represented by formula (3): wherein R1 represents an alkyl group having 1 to 10 carbon atoms or the like, R3 represents a hydrogen atom or the like, Me represents a methyl group, m represents an integer of 1 to 3, and n represents an integer of 1 to 12, wherein R2 represents a hydrogen atom or the like, and R1, Me, m, and n represent the same meaning as described above; and (II): a step of further reacting by supplying the amino group-containing organosilicon compound represented by formula (3) to a mixture containing a compound represented by formula (1) and urea.Type: ApplicationFiled: September 17, 2019Publication date: March 19, 2020Applicant: Shin-Etsu Chemical Co., Ltd.Inventors: Munenao HIROKAMI, Katsuhiro UEHARA, Toru IIJIMA
-
Publication number: 20200079652Abstract: A carbon nanotube array constituted by large numbers of carbon nanotubes vertically aligned on a substrate is produced by supplying a carbon source gas into a reaction vessel having a hydrogen gas atmosphere, in which a substrate on which a reaction catalyst comprising fine metal particles is formed is placed; forming large numbers of vertically aligned carbon nanotubes on the substrate by keeping a reaction temperature of 500-1100° C. for 0.5-30 minutes; and heat-treating the carbon nanotubes by stopping the supply of the carbon source gas and keeping 400-1100° C. for 0.5-180 minutes in a non-oxidizing atmosphere.Type: ApplicationFiled: March 22, 2019Publication date: March 12, 2020Applicant: SUGITA DENSEN CO., LTD.Inventors: Kenta NAKA, Toru IIJIMA, Yuichi SUNAGA, Akikazu SUGITA, Shuji TSURUOKA
-
Patent number: 10519150Abstract: The present invention provides novel pharmaceutically acceptable salts of a morpholine derivative, including a malate, a tartrate, a hydrochloride, an acetate, and a naphthalene disulfonate thereof, wherein the tartrate has 3 crystal salt forms: crystal form A, crystal form B and dihydrate; the malate, the hydrochloride, and the acetate each have one crystal salt form; the naphthalene disulfonate is amorphous. When compared to the known morpholine derivative free base, the present invention has one or more improved properties, e.g., a better crystalline state, greatly improved water solubility, light stability and thermal stability, etc. The present invention further provides preparation methods for the salts of morpholine derivative and the crystal forms thereof, pharmaceutical compositions and use thereof.Type: GrantFiled: December 29, 2016Date of Patent: December 31, 2019Assignee: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Guangxin Xia, Jianshu Xie, Guohui Jia, Jiansheng Han, Naoko Ueda, Toru Iijima
-
Patent number: 10519806Abstract: In a turbine housing that includes a scroll portion constituting a spiral exhaust gas passage between an exhaust inlet side flange constituting an inlet for exhaust gas and an exhaust outlet side flange constituting an outlet for the exhaust gas, the turbine housing discharging the exhaust gas to an exhaust outlet side through a turbine wheel disposed in a central portion of the scroll portion, a part of a passage face of the exhaust gas passage, in the scroll portion, is formed from a scroll member made of a casting.Type: GrantFiled: November 2, 2016Date of Patent: December 31, 2019Assignee: CALSONIC KANSEI CORPORATIONInventors: Satoru Yokoshima, Toru Iijima, Naoki Tobari, Yasunori Kozuka, Takaharu Yamamoto
-
Publication number: 20190016718Abstract: The present invention provides novel pharmaceutically acceptable salts of a morpholine derivative, including a malate, a tartrate, a hydrochloride, an acetate, and a naphthalene disulfonate thereof, wherein the tartrate has 3 crystal salt forms: crystal form A, crystal form B and dihydrate; the malate, the hydrochloride, and the acetate each have one crystal salt form; the naphthalene disulfonate is amorphous. When compared to the known morpholine derivative free base, the present invention has one or more improved properties, e.g., a better crystalline state, greatly improved water solubility, light stability and thermal stability, etc. The present invention further provides preparation methods for the salts of morpholine derivative and the crystal forms thereof, pharmaceutical compositions and use thereof.Type: ApplicationFiled: December 29, 2016Publication date: January 17, 2019Applicants: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD., MITSUBISHI TANABE PHARMA CORPORATIONInventors: Guangxin XIA, Jianshu XIE, Guohui JIA, Jiansheng HAN, Naoko UEDA, Toru IIJIMA
-
Patent number: 10155731Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: GrantFiled: January 12, 2016Date of Patent: December 18, 2018Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai
-
Publication number: 20180328226Abstract: In a turbine housing that includes a scroll portion constituting a spiral exhaust gas passage between an exhaust inlet side flange constituting an inlet for exhaust gas and an exhaust outlet side flange constituting an outlet for the exhaust gas, the turbine housing discharging the exhaust gas to an exhaust outlet side through a turbine wheel disposed in a central portion of the scroll portion, a part of a passage face of the exhaust gas passage, in the scroll portion, is formed from a scroll member made of a casting.Type: ApplicationFiled: November 2, 2016Publication date: November 15, 2018Applicant: CALSONIC KANSEI CORPORATIONInventors: Satoru YOKOSHIMA, Toru IIJIMA, Naoki TOBARI, Yasunori KOZUKA, Takaharu YAMAMOTO
-
Patent number: 9751846Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: July 8, 2016Date of Patent: September 5, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Patent number: 9556159Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R1 is a cycloalkyl group or an alkyl, R22 is an optionally substituted aryl and the like, R is a lower alkyl group, R3, R4, R5 and R6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 13, 2013Date of Patent: January 31, 2017Assignees: Mitsubishi Tanabe Pharma Corporation, Shanghai Pharmaceuticals Holding Co., Ltd.Inventors: Toru Iijima, Yoichi Takahashi, Miki Hirai, Hiroshi Sugama, Yuko Togashi, Jingkang Shen, Guangxin Xia, Huixin Wan
-
Publication number: 20160362385Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: ApplicationFiled: July 8, 2016Publication date: December 15, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki OKABE, Takeshi HAMADA, Kaori TOMIKAWA, Yukie OKAMOTO, Toru IIJIMA, Hidenori AKATSUKA, Kenichi TOYAMA, Atsushi MORODA, Yoshihiro SUGIURA
-
Patent number: 9409874Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: August 8, 2013Date of Patent: August 9, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Publication number: 20160145220Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: ApplicationFiled: January 12, 2016Publication date: May 26, 2016Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru IIJIMA, Hiroshi SUGAMA, Takayuki KAWAGUCHI, Jingkang SHEN, Guangxin XIA, Jianshu XIE, Miki HIRAI
-
Patent number: 9278944Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: GrantFiled: March 15, 2012Date of Patent: March 8, 2016Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai
-
Publication number: 20150232459Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R1 is a cycloalkyl group or an alkyl, R22 is an optionally substituted aryl and the like, R is a lower alkyl group, R3, R4, R5 and R6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 13, 2013Publication date: August 20, 2015Applicants: Shanghai Pharmaceuticals Holding CO., LTD., MITSUBISHI TANABE PHARMA CORPORATIONInventors: Toru Iijima, Yoichi Takahashi, Miki Hirai, Hiroshi Sugama, Yuko Togashi, Jingkang Shen, Guangxin Xia, Huixin Wan
-
Publication number: 20150218113Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: ApplicationFiled: August 8, 2013Publication date: August 6, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Patent number: 8975252Abstract: The present invention provides a morpholine derivative of the formula [I]; wherein R1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R3, R4, R5 and R6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.Type: GrantFiled: June 16, 2008Date of Patent: March 10, 2015Assignees: Shanghai Pharmaceuticals Holding Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Hidenori Akatsuka, Hiroshi Sugama, Nobumasa Awai, Takayuki Kawaguchi, Yoichi Takahashi, Toru Iijima, Jingkang Shen, Guangxin Xia, Jianshu Xie